ADMA Biologics Files 8-K with Financials
Ticker: ADMA · Form: 8-K · Filed: Aug 14, 2024 · CIK: 1368514
| Field | Detail |
|---|---|
| Company | Adma Biologics, Inc. (ADMA) |
| Form Type | 8-K |
| Filed Date | Aug 14, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $30 million, $72.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: ADMA
TL;DR
ADMA Biologics filed an 8-K with updated financials and exhibits.
AI Summary
On August 14, 2024, ADMA Biologics, Inc. filed an 8-K report. The filing primarily concerns the submission of financial statements and exhibits, with no other specific events detailed in the provided excerpt.
Why It Matters
This filing indicates that ADMA Biologics is providing updated financial information and exhibits to the SEC, which is standard for public companies and important for investors to review for financial health.
Risk Assessment
Risk Level: low — This filing is a routine submission of financial statements and exhibits, not indicating any immediate operational or financial distress.
Key Players & Entities
- ADMA BIOLOGICS, INC. (company) — Registrant
- August 14, 2024 (date) — Date of Report
- 001-36728 (company) — SEC File Number
- 56-2590442 (company) — IRS Employer Identification No.
- Ramsey, New Jersey (location) — Principal executive offices
- 201-478-5552 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by ADMA Biologics?
The primary purpose of this 8-K filing is to report Other Events and to submit Financial Statements and Exhibits as of August 14, 2024.
What is the exact date of the report for ADMA Biologics?
The exact date of the report is August 14, 2024.
What is ADMA Biologics, Inc.'s SEC File Number?
ADMA Biologics, Inc.'s SEC File Number is 001-36728.
Where are ADMA Biologics, Inc.'s principal executive offices located?
ADMA Biologics, Inc.'s principal executive offices are located at 465 State Route 17, Ramsey, New Jersey 07446.
Does the filing indicate any specific new events or material changes for ADMA Biologics?
Based on the provided excerpt, the filing primarily concerns 'Other Events' and 'Financial Statements and Exhibits,' with no specific new events or material changes detailed.
Filing Stats: 441 words · 2 min read · ~1 pages · Grade level 10.3 · Accepted 2024-08-14 09:05:31
Key Financial Figures
- $30 million — s release announcing that it has repaid $30 million from its original $72.5 million revolvi
- $72.5 million — as repaid $30 million from its original $72.5 million revolving credit facility with Ares Cap
Filing Documents
- ef20034127_8k.htm (8-K) — 29KB
- ef20034127_ex99-1.htm (EX-99.1) — 10KB
- 0001140361-24-037184.txt ( ) — 173KB
- adma-20240814.xsd (EX-101.SCH) — 4KB
- adma-20240814_lab.xml (EX-101.LAB) — 21KB
- adma-20240814_pre.xml (EX-101.PRE) — 16KB
- ef20034127_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events On August 14, 2024, ADMA Biologics, Inc. issued a press release announcing that it has repaid $30 million from its original $72.5 million revolving credit facility with Ares Capital Corporation and certain affiliated credit funds. A copy of the press release is attached as Exhibit 99.1 and incorporated by reference herein.
01
Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 99.1 ADMA Biologics, Inc. Press Release, dated August 14, 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. August 14, 2024 ADMA Biologics, Inc. By: /s/ Adam S. Grossman Name: Adam S. Grossman Title: President and Chief Executive Officer 3